LumiThera
Tracy C. Puckett is the Vice President of Marketing for LumiThera. Mrs. Puckett has been the Principal of Trinity Fair Consulting Group since 2015. Ms. Puckett has global brand strategy and product launch experience in packaged goods, medical device and pharmaceutical products. Prior to forming her own consultancy, she served as Vice President of Marketing at TearLab Corporation, Executive Director of Branding at Alimera Sciences and Executive Director of US Marketing at Novartis Ophthalmics. Mrs. Puckett managed the Novartis Ophthalmics account at Adair-Greene prior to joining Novartis Ophthalmics. International consumer experience was achieved at McCann-Erickson in Moscow, Russia, a multi-national advertising agency where she headed a New Business team and served as Group Account Supervisor for a diverse brand team, managing clients such as Johnson & Johnson, Nestle, and Gillette. Throughout her career, she has successfully built sustainable brand propositions which met company P&L objectives. She earned a Bachelor of Science in Psychology from Georgia Southern University.
This person is not in any offices
LumiThera
1 followers
At LumiThera, they are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. They will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company’s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area.